Other Issues

Browse Other Issues Content

CHPA, which represents leading manufacturers of OTC cough medicines, strongly supports this legislation and is joined many by substance abuse prevention organizations such as the Community Anti-Drug Coalitions of America and the Partnership for Drug-Free Kids.

Apr 20, 2016

CHPA released the following statement today in support of a Florida law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

Apr 1, 2016

In general, CHPA supports FDA's intent to harmonize the requirements for Rx and OTC products and make them consistent with long-standing Agency policy.

Mar 22, 2016

CHPA appreciates the opportunity to provide information on features to add and potential functionality improvements to make the Dietary Supplement Label Database a more useful tool for regulators, consumers, and other users of the database.

Dec 31, 2015

CHPA supports EPA's efforts to streamline regulations under RCRA. CHPA has two central comments on the proposal.

Dec 23, 2015

CHPA commends the U.S. House of Representatives for swift passage of the Microbead-Free Waters Act of 2015 (H.R. 1321).

Dec 7, 2015

CHPA supports improving the compendial test methods and establishing product standards for the variety of dosage forms, which can provide an additional measure of safety for OTC products.

Nov 30, 2015

CRN, CHPA, and their member companies are concerned with and offer the following comments to the proposed revisions to the USP-NF General Chapter <467> on Residual Solvents.

Nov 27, 2015

Comments regarding the Agency’s goals behind the proposed quality metrics program.

Nov 25, 2015

Our member companies support the concept that well-designed metrics are critical in driving and measuring continuous improvement activities in both quality systems and improving manufacturing processes.

Nov 24, 2015

Filter Results